Pancreatic cancer is one of the deadliest cancers, with patients surviving on average less than a year once the disease has spread. There is an urgent need to evaluate more therapeutic targets. The chemotherapeutic agent abemaciclib is effective in treating breast cancer, but there is limited preclinical evaluation of this targeted therapy in treating pancreatic cancer.
New research from Sidney Kimmel Cancer Center — Jefferson Health (SKCC) provides evidence supporting the use of abemaciclib for pancreatic cancer, and suggests new targets that could improve the efficacy of the drug and break a common problem of drug resistance in this disease. The study was published in Molecular Cancer Research on August 5. Read more . . .